Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide-Reference-Cited by-同舟云学术

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide

Published:2008-06 Issue:6 Volume:18 Page:515-523
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Ekhart Corine,Doodeman Valerie D.,Rodenhuis Sjoerd,Smits Paul H.M.,Beijnen Jos H.,Huitema Alwin D.R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference48 articles.

1. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles;Roy;Drug Metab Dispos,1999

2. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione;Dirven;Cancer Res,1994

3. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines;Sladek;Curr Pharm Des,1999

4. Clinical pharmacokinetics of cyclophosphamide;de Jonge;Clin Pharmacokinet,2005

5. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin;Huitema;Ann Oncol,2002

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics;Advances in Pharmacological and Pharmaceutical Sciences;2024-01

2. Emerging Pathophysiology and Treatment of Prostate Cancer: Future Perspective;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

3. Genetic polymorphisms effect on cyclophosphamide’s tolerability and clinical efficacy in Egyptian patients with lupus nephritis;Pharmacogenetics and Genomics;2023-08-24

4. Pharmacogenomics in allogeneic hematopoietic stem cell transplantation: Implications on supportive therapies and conditioning regimens;Best Practice & Research Clinical Haematology;2023-06

5. Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan;Bone Marrow Transplantation;2023-04-21